Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program

Boehringer Ingelheim said it will end research into developing a porcine circovirus type 2 ready-to-use (RTU) vaccine combination to focus its attention on its PCV2 Mycoplasma hyopneumoniae (M. hyo) vaccine.

The company said its research program found that the best protection against both pathogens was found in its vaccines when freshly mixed and used as recommended. Although early data showed promise, the RTU combination didn't reach company standards for efficacy and safety.

Boehringer's FLEXcombo platform of mixable vaccines protects pigs against both PCV2 and M. hyo in a single dose. Its MycoFLEX headspace bottle, which was introduced last year, allows farmers to mix the two pig vaccines for a single application.

The same concept is used for several other of the company's animal pharmaceuticals and is licensed in North America and several Asian countries.

- see the release

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint…

Miami-based biotech Opko Health is branching out into animal health, joining one of the fastest growing segments of the industry: oncology. But the company--…